원료의약품(API) 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 합성 유형별, 용도별, 지역별, 경쟁별(2020-2030년)
Active Pharmaceutical Ingredient Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type of Synthesis, By Application, By Region and Competition, 2020-2030F
상품코드:1763961
리서치사:TechSci Research
발행일:2025년 06월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
원료의약품(API) 세계 시장은 2024년에 1,554억 1,000만 달러로 평가되었으며, 2030년에는 2,276억 7,000만 달러에 달할 것으로 예측되며, 예측 기간 동안 CAGR 6.77%로 성장합니다.
제약사들이 암, 심혈관질환, 신경질환, 당뇨병, 호흡기질환 등 다양한 질환에 대한 치료 포트폴리오를 확장함에 따라 API에 대한 수요가 꾸준히 증가하고 있습니다. 이러한 급격한 증가는 전 세계적으로 만성질환에 대한 부담 증가, 인구 고령화, 라이프스타일의 변화에 기인한 것으로 분석됩니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
1,554억 1,000만 달러
시장 규모 : 2030년
2,276억 7,000만 달러
CAGR : 2025-2030년
6.77%
급성장 부문
바이오테크놀러지
최대 시장
북미
시장 환경은 우수의약품제조관리기준(GMP)과 엄격한 품질 관리 기준에 초점을 맞춘 규제 강화로 인해 형성되고 있습니다. 원료의약품 제조업체들은 첨단 기술에 대한 투자, 공정 자동화 개선, 환경적 지속가능성을 우선순위에 두고 대응하고 있습니다. 세계 공급망이 계속 다양화되는 가운데, 경쟁력을 유지하고 제약 부문의 역동적인 요구에 부응하기 위해서는 규제 대응, 인프라, 지리적 탄력성에 대한 전략적 투자가 계속 필수적입니다.
The Global Active Pharmaceutical Ingredient (API) Market was valued at USD 155.41 Billion in 2024 and is projected to reach USD 227.67 Billion by 2030, growing at a CAGR of 6.77% during the forecast period. Demand for APIs is rising steadily as pharmaceutical companies broaden their therapeutic portfolios to address a wide array of conditions including oncology, cardiovascular ailments, neurological disorders, diabetes, and respiratory diseases. This surge is largely driven by the growing global burden of chronic illnesses, an aging population, and evolving lifestyle factors.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 155.41 Billion
Market Size 2030
USD 227.67 Billion
CAGR 2025-2030
6.77%
Fastest Growing Segment
Biotech
Largest Market
North America
The market landscape is being shaped by increasing regulatory scrutiny focused on Good Manufacturing Practices (GMP) and stringent quality control standards. API manufacturers are responding by investing in advanced technologies, improving process automation, and prioritizing environmental sustainability. As global supply chains continue to diversify, strategic investment in regulatory compliance, infrastructure, and geographic resilience will remain essential for manufacturers seeking to maintain competitiveness and meet the dynamic needs of the pharmaceutical sector.
Key Market Drivers
Growth in Healthcare Industry
The continued expansion of the global healthcare sector is a primary catalyst for growth in the API market. With healthcare spending exceeding USD 4 trillion annually, pharmaceuticals and biotechnology account for a significant portion-over USD 850 billion-underscoring the vital role APIs play in medical innovation and treatment delivery.
The escalating prevalence of chronic conditions such as cardiovascular diseases, cancer, and diabetes has led to a sharp increase in demand for high-quality, effective APIs. In 2021, noncommunicable diseases (NCDs) accounted for around 43 million deaths worldwide, representing approximately 75% of all non-pandemic-related fatalities. These health burdens drive the need for long-term medication use, prompting pharmaceutical companies to ramp up API production to meet growing therapeutic demands. The development of biologics and high-potency APIs (HPAPIs) further reflects the healthcare sector's focus on targeted, personalized treatments, reinforcing sustained market growth.
Key Market Challenges
High Cost of Production
High production costs present a substantial barrier in the global API market, affecting both manufacturer margins and the affordability of end products. These costs stem from intricate synthesis procedures, rigorous quality and safety requirements, and the rising expense of sourcing raw materials.
Complying with Good Manufacturing Practices (GMP) mandates the use of highly specialized equipment, skilled personnel, and continuous quality assurance efforts, significantly elevating both capital and operational expenditures-particularly in developed markets. Additionally, maintaining consistent output quality, ensuring regulatory compliance, and managing environmentally sustainable operations add further financial strain. This economic burden restricts entry for smaller firms and contributes to price volatility, especially in regions with limited manufacturing infrastructure.
Key Market Trends
Rise of Peptide and Oligonucleotide APIs
A prominent trend shaping the API market is the surge in demand for peptide and oligonucleotide APIs, driven by the global push toward precision medicine and biologically targeted therapies. GLP-1 analogs like semaglutide and liraglutide are gaining attention in the generics segment, particularly for their effectiveness in treating diabetes and obesity.
Peptides, with their high specificity and minimal toxicity, are increasingly used in treating cancers and metabolic or rare genetic disorders. Likewise, oligonucleotide APIs, composed of DNA or RNA sequences, allow for therapeutic targeting at the genetic level, opening new treatment avenues for diseases previously considered intractable. These innovations support the pharmaceutical industry's pivot to high-efficacy treatments, marking a shift from conventional small-molecule drugs to advanced, biologically complex APIs.
Key Market Players
Teva Pharmaceutical Industries Ltd.
Bristol-Myers Squibb Company
Boehringer Ingelheim GmbH
Merck & Co., Inc.
GlaxoSmithKline Plc
Novartis International AG
F. Hoffmann-La Roche AG
Sanofi S.A.
Eli Lilly and Company
AbbVie Inc
Report Scope
In this report, the Global Active Pharmaceutical Ingredient Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Active Pharmaceutical Ingredient Market, By Type of Synthesis:
Biotech
Fermentation
Plant Extracts
Synthetic
Active Pharmaceutical Ingredient Market, By Application:
Cardiovascular Disease
Oncology
Neurological Disorders
Orthopedic Disorders
Respiratory
Gastrointestinal Disorders
Urology
Others
Active Pharmaceutical Ingredient Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Active Pharmaceutical Ingredient Market.
Available Customizations
Global Active Pharmaceutical Ingredient Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. Impact of COVID-19 on Global Active Pharmaceutical Ingredient Market
5. Global Active Pharmaceutical Ingredient Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type of Synthesis (Biotech, Fermentation, Plant Extracts, Synthetic)
